Literature DB >> 20443037

Virtual screening of specific chemical compounds by exploring E.coli NAD+-dependent DNA ligase as a target for antibacterial drug discovery.

Bashir Akhlaq Akhoon1, Shishir K Gupta, Gagan Dhaliwal, Mugdha Srivastava, Shailendra K Gupta.   

Abstract

Unique substrate specificity compared with ATP-dependent human DNA ligases recommends E.coli NAD(+)-ligases as potential targets. A plausible strategy is to identify the structural components of bacterial DNA ligase that interact with NAD(+) and then to isolate small molecules that recognize these components and thereby block the binding of NAD(+) to the ligase. This work describes a molecular modeling approach to detect the 3D structure of NAD(+)-dependent DNA ligase in E. coli whose partial structure was determined by wet lab experiments and rest structure was left as such on the road for repairment. We applied protein-drug docking approach to detect the binding affinity of this enzyme with Quinacrine and some of its virtual derivatives. In silico docking results predict that the virtual derivative of Quinacrine (C21H26ClN3O2) has greater binding affinity than Quinacrine. Drug likeness value of 0.833 was observed for this derivative without showing any toxicity risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443037     DOI: 10.1007/s00894-010-0713-9

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  39 in total

1.  Geno3D: automatic comparative molecular modelling of protein.

Authors:  Christophe Combet; Martin Jambon; Gilbert Deléage; Christophe Geourjon
Journal:  Bioinformatics       Date:  2002-01       Impact factor: 6.937

2.  Cofactor binding modulates the conformational stabilities and unfolding patterns of NAD(+)-dependent DNA ligases from Escherichia coli and Thermus scotoductus.

Authors:  Daphné Georlette; Vinciane Blaise; Christophe Dohmen; Fabrice Bouillenne; Benjamin Damien; Eric Depiereux; Charles Gerday; Vladimir N Uversky; Georges Feller
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

3.  SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID.

Authors:  S N COHEN; K L YIELDING
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

4.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

Review 5.  Virtual screening of chemical libraries.

Authors:  Brian K Shoichet
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

Review 6.  DNA ligases: structure, reaction mechanism, and function.

Authors:  Alan E Tomkinson; Sangeetha Vijayakumar; John M Pascal; Tom Ellenberger
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

7.  Functional domains of an NAD+-dependent DNA ligase.

Authors:  D J Timson; D B Wigley
Journal:  J Mol Biol       Date:  1999-01-08       Impact factor: 5.469

8.  Mutational analyses of Aquifex pyrophilus DNA ligase define essential domains for self-adenylation and DNA binding activity.

Authors:  J H Lim; J Choi; W Kim; B Y Ahn; Y S Han
Journal:  Arch Biochem Biophys       Date:  2001-04-15       Impact factor: 4.013

9.  NAD+-dependent DNA ligase encoded by a eukaryotic virus.

Authors:  V Sriskanda; R W Moyer; S Shuman
Journal:  J Biol Chem       Date:  2001-07-17       Impact factor: 5.157

10.  Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I.

Authors:  Sandeep Kumar Srivastava; Divya Dube; Neetu Tewari; Namrata Dwivedi; Rama Pati Tripathi; Ravishankar Ramachandran
Journal:  Nucleic Acids Res       Date:  2005-12-15       Impact factor: 16.971

View more
  1 in total

1.  Identification of Novel Inhibitors of Escherichia coli DNA Ligase (LigA).

Authors:  Arqam Alomari; Robert Gowland; Callum Southwood; Jak Barrow; Zoe Bentley; Jashel Calvin-Nelson; Alice Kaminski; Matthew LeFevre; Anastasia J Callaghan; Helen A Vincent; Darren M Gowers
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.